For & Against
What's Next
The next 3–6 months are unusually loaded for a name this small. Two prints that arrive before mid-August will settle the central operating question, and the second tranche of the founder-and-Trustar convertible will be deployed into the same window. Today is 2026-04-27.
What the market is watching most closely. Two numbers, in this order: (1) S&M as a percent of revenue in Q1 2026 — the single line item that printed at 64.8% in Q4 2025 and that the entire FY2026 thesis depends on drifting back into the 50s; (2) non-GAAP operating margin holding at or above zero — the four-quarter compression trajectory crossing the breakeven line in print, not in adjustment. The convertible second tranche and any acquisition announcement will be read in the context of those two prints. Management has guided Q1 2026 net revenue to ¥958.6M–¥1.08B (+15% to +30% YoY); the consensus expectation is that the midpoint comes in but the cost line is the real test.
For / Against / My View
The Bull and Bear cases below are drawn directly from bull-claude.md and bear-claude.md — three sharpest points each, evidence intact. The Tensions section identifies where the two essays argue about the same fact and the signal that resolves each.
For
Net cash and short-term investments of ¥1.05B sit inside a ¥1.87B market cap. After backing out cash, a 78%-gross-margin, ¥4.3B-revenue brand portfolio with zero financial debt is being priced at roughly ¥800M — about 0.19x the revenue it generated last year, an order of magnitude below every named peer.
Numbers — "EV/Revenue of 0.06x — net of cash, the operating business is being priced near zero." Business — "Cash + ST inv ¥1054M FY2025."
Quarterly operating margin has marched from −34.0% (Q4 2024) to −4.1%, −5.1%, −8.4%, and −0.9% (Q4 2025). Revenue reaccelerated to +18% YoY in Q4 2025, gross margin printed 79.2% (up 210 bps YoY), and FY2025 closed non-GAAP positive (¥8.4M) for the first time since 2019. Skincare crossed 53% of mix for the year and 61% in Q4.
Numbers — "four straight quarters of compressing operating losses, while revenue re-accelerated to +18% YoY in Q4. This is the 'is the corner real?' chart."
In March 2026, CEO Jinfeng Huang personally subscribed to roughly half of a US$120M (≈¥834M) convertible private placement alongside Trustar Capital. At a 89% drawdown from the all-time high, with the founder already holding 35% of the economics and 91% of the votes, it is the strongest available "I believe what I'm telling you" disclosure. The capital is earmarked for R&D, international expansion and skincare M&A.
People — "March 2026 — CEO + Trustar Capital convertible subscription, ¥834M, BUY"; "Founders rarely write personal cheques into the converts of their own listed company; when they do, it is the strongest available form of 'I believe what I'm telling you' disclosure."
Bull Price Target (¥ per ADS-equivalent)
Timeline
Bull's primary catalyst: Q1 and Q2 2026 prints inside the +15% to +30% revenue guidance with non-GAAP operating margin holding at or above zero — the four-quarter trajectory crossing the breakeven line in print, not in adjustment. Skincare share crossing 60% for FY2026 is the second leg. Bull's disconfirming signal: S&M as a percent of revenue staying above 65% for two consecutive non-Q4 (non-Double-11) quarters, or a third goodwill writedown — either on existing Eve Lom carrying value or on a freshly-deployed Trustar convertible acquisition.
Against
Management's entire sell-side story is that selling & marketing intensity drifts into the 50s and operating leverage compounds. Q4 2025 — the supposed "vindication" quarter — printed S&M at 64.8% of revenue, up from 60.1% in Q4 2024. The single number on which the FY2026 thesis depends just moved against the thesis on the most recent print, in the most important traffic quarter of the year.
Warren tab — "S&M was 64.8% of revenue in Q4 2025, up from 60.1% in Q4 2024 because of Double 11 traffic inflation"; explicit alert flagged as "the warning signal of the moment." Quant tab confirms FY2025 op margin of −4.3% — the eighth straight year without an operating yuan.
Of ¥6.68B raised at IPO, roughly ¥4.6B has been consumed by operating losses and acquisition writedowns; ¥757M of goodwill on Eve Lom alone has been impaired across two writedowns (¥354M FY2023 + ¥403M FY2024). The March 2026 Trustar convertible is earmarked for "acquisitions and international expansion" — the exact mandate that produced Eve Lom and EANTiM. Same CEO, same plan administrator, same "premium brand portfolio" framing.
Quant tab — "Of the ¥6.68B raised at the 2020 IPO, roughly ¥4.6B has been consumed by operating losses and acquisition writedowns." Historian tab — "What still looks stretched: The Eve Lom thesis. ¥757M of cumulative goodwill impaired against the original 2021 purchase price."
The CEO holds 35% of the economics and 91% of the vote via a 20-vote Class B share. The 2022 evergreen plan dilutes at 1.0–1.5% per year for a decade, and the CEO is the plan administrator with no compensation consultant disclosed. Related-party purchases from companies under his control have doubled in two years (¥137.5M → ¥285.5M, now 8.3% of revenue). If the operating turn happens, there is no contractual mechanism for the value to accrue to minority holders.
Sherlock tab — "The 20-vote Class B class gives one person 91% of the vote in perpetuity"; "Purchases from companies under Yatsen's 'significant control' have doubled in two years — ¥137.5M → ¥285.5M — and now equal 8.3% of FY2024 revenue."
Bear Downside Target (¥ per ADS-equivalent)
Timeline
Bear's primary trigger: Q1 2026 print fails to hold S&M below 60%, or management announces a premium-skincare acquisition above ¥500M before two clean operating-positive quarters. Bear's covering signal: Two consecutive quarters of S&M below 58% of revenue and non-GAAP operating margin above zero without a corresponding skincare-share retrenchment.
The Tensions
1. Q4 2025 — vindication or warning?
Bull reads Q4 2025 as the inflection: operating margin compressed from −34% (Q4 2024) all the way to −0.9% on +18% revenue, gross margin 79.2%, the four-quarter chart that the equity is refusing to re-rate. Bear reads the same quarter as the warning: selling & marketing jumped to 64.8% of revenue from 60.1% the prior Q4, and that is the very line item the FY2026 thesis depends on. Both cite the Q4 2025 print. This resolves on the Q1 2026 print, due mid-May 2026 — specifically whether S&M holds below 60% and non-GAAP operating margin sits at or above zero. Both, or the bull case is finished for at least another quarter.
2. The Trustar convertible — alignment or value extraction?
Bull reads CEO Huang personally writing ~¥417M into the convertible at a 89% drawdown as the strongest available "I believe" disclosure — a founder doubling down with personal capital. Bear reads the same deal as a related-party financing where the controlling shareholder gets a 1.5% coupon, a 20% conversion premium, and warrants equal to one-tenth of conversion shares — terms minority holders cannot match — with proceeds explicitly earmarked for the same "premium brand acquisition + international expansion" mandate that produced ¥757M of Eve Lom impairments. Both cite the March 2026 ¥834M Trustar convertible. This resolves on how the proceeds are deployed by Q3 2026 — a sub-¥500M bolt-on or a buyback signals discipline; another ¥500M-plus premium-brand acquisition before two clean operating-positive quarters confirms the bear's "lessons-of-2021-not-learned" framing.
3. The ¥1.05B net cash position — downside floor or M&A war chest?
Bull reads ¥1.05B of cash and short-term investments inside a ¥1.87B market cap as the downside floor — the operating business is being priced near zero against a balance sheet with zero financial debt. Bear reads the same ¥1.05B as not a floor for minority holders because the cash is earmarked for acquisitions and overseas expansion, not buybacks, and the eight-year track record is ¥4.6B of IPO money consumed by operating losses and writedowns. Both cite the FY2025 year-end cash position. This resolves on the next capital-allocation decision — a buyback authorisation or a sub-¥200M tuck-in proves the floor is real; a ¥500M-plus premium-brand acquisition proves the cash is dry powder for the same playbook.
My View
Close call but the slight edge sits with the bear. The single sharpest datum on the page is that S&M ratio printing 64.8% in the very quarter the bull case rests on — management's primary operating lever moved against the thesis on the most recent print, in the most important quarter of the year, and that's not noise. The Trustar convertible compounds the worry rather than resolving it: when a 91%-voting founder takes related-party paper in his own company at the bottom on cheap terms, it can be alignment, but it can also be the only-buyer signal, and the earmark — premium-brand M&A and overseas expansion — points back at the exact playbook that produced ¥757M of Eve Lom impairments. I'd wait for the Q1 2026 print due mid-May. The condition that would flip me toward the bull side: Q1 2026 prints S&M below 60% AND non-GAAP operating margin at or above zero, with skincare share holding above 60%. That is the same data point the bear used to dismiss the inflection — if it travels into a non-Double-11 quarter, the trough multiple becomes interesting in a way it isn't today.